Frans S. S. Leijten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Frans S. S. Leijten has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Maeike Zijlmans
Department of Neurology and Neurosurgery University Medical Center, Utrecht Brain Center, member of European Reference Network EpiCARE Utrecht the Netherlands
3 shared publications - Geertjan J.M. Huiskamp
UMC Utrecht Brain Center, Department of Neurology and Neurosurgery, University Medical Center Utrecht, PO Box 85500, 3584 GA Utrecht, The Netherlands
2 shared publications - Kees P. J. Braun
Department of Child Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Member of ERN-EpiCARE, Utrecht, The Netherlands
2 shared publications - Maryse A. van 'T Klooster
Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
2 shared publications - Albert J. Colon
Academic Center for Epileptology, Kempenhaeghe, Heeze, Netherlands
1 shared publication Alexander C. Van Huffelen
Department of Clinical Neurophysiology, Rudolf Magnus Institute of Neuroscience and University Medical Center Utrecht, UMC Utrecht, Utrecht, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 28 June 2024
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 46 (5) , 642-648
Association of Lamotrigine Plasma Concentrations With Efficacy and Toxicity in Patients With Epilepsy: A Retrospective Study
Background: There is limited evidence to support the currently suggested lamotrigine (LTG) therapeutic reference range of 2.5–15 mg/L for the treatment of seizures. The objective of this study was to evaluate the association of LTG plasma concentrations with the efficacy and toxicity of the treatment in patients with epilepsy. Methods: Patients whose LTG plasma concentration was measured between January 2013 and February 2022 were included. Efficacy was defined as seizure freedom for at least 6 months around the time of measured LTG concentration. Toxicity was defined as any LTG-related adverse drug effect documented in each patient's health record or when the reason for measuring the LTG concentration was toxicity. In addition, the dose–concentration relationship of LTG was assessed. Results: In total, 549 concentrations from 259 patients with epilepsy were included. The most common reasons for therapeutic drug monitoring were suspected inefficacy (39%) and pregnancy (21%). The LTG plasma concentration was not associated with efficacy (adjusted odds ratio = 0.94; 95% confidence interval, 0.85–1.04). The LTG plasma concentration was positively associated with the incidence of toxicity after adjusting for age, sex, and number of antiepileptic drugs (odds ratio = 1.11; 95% confidence interval, 1.04–1.19). The daily dose had a significant linear correlation with the LTG plasma concentration (P < 0.001). Conclusions: The LTG plasma concentration was associated with toxicity, whereas no association with efficacy was found. A reference range of 2.5–10 mg/L may be considered to decrease the risk of toxicity while maintaining similar efficacy. Therapeutic drug monitoring may be useful when LTG-related toxicity is suspected and in cases of pharmacokinetic changes (eg, pregnancy and concomitant use of interacting drugs) that can influence the LTG plasma concentration.
- 28 June 2024
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 46 (5) , 642-648
Open AccessAssociation of Lamotrigine Plasma Concentrations With Efficacy and Toxicity in Patients With Epilepsy: A Retrospective Study
Background: There is limited evidence to support the currently suggested lamotrigine (LTG) therapeutic reference range of 2.5–15 mg/L for the treatment of seizures. The objective of this study was to evaluate the association of LTG plasma concentrations with the efficacy and toxicity of the treatment in patients with epilepsy. Methods: Patients whose LTG plasma concentration was measured between January 2013 and February 2022 were included. Efficacy was defined as seizure freedom for at least 6 months around the time of measured LTG concentration. Toxicity was defined as any LTG-related adverse drug effect documented in each patient's health record or when the reason for measuring the LTG concentration was toxicity. In addition, the dose–concentration relationship of LTG was assessed. Results: In total, 549 concentrations from 259 patients with epilepsy were included. The most common reasons for therapeutic drug monitoring were suspected inefficacy (39%) and pregnancy (21%). The LTG plasma concentration was not associated with efficacy (adjusted odds ratio = 0.94; 95% confidence interval, 0.85–1.04). The LTG plasma concentration was positively associated with the incidence of toxicity after adjusting for age, sex, and number of antiepileptic drugs (odds ratio = 1.11; 95% confidence interval, 1.04–1.19). The daily dose had a significant linear correlation with the LTG plasma concentration (P < 0.001). Conclusions: The LTG plasma concentration was associated with toxicity, whereas no association with efficacy was found. A reference range of 2.5–10 mg/L may be considered to decrease the risk of toxicity while maintaining similar efficacy. Therapeutic drug monitoring may be useful when LTG-related toxicity is suspected and in cases of pharmacokinetic changes (eg, pregnancy and concomitant use of interacting drugs) that can influence the LTG plasma concentration.
- Open Access
- 13 December 2023
- Published by Nederlandse Liga tegen Epilepsie in Epilepsie, periodiek voor professionals
- Vol. 22 (4)
De REC2STIM-studie: corticale netwerkstimulatie in een nieuw jasje
Binnenkort zal klinisch technoloog Dorien van Blooijs promoveren op corticale netwerkstimulatie als behandeling voor epilepsie. De totstandkoming van haar REC2STIM- studie heeft veel voeten in de aarde gehad, maar levert opmerkelijke inzichten en resultaten op. Daarnaast heeft zij met de spin-off van dit project een geweldige bijdrage geleverd aan de fysiologische kennis over de hersenen. Haar promotietraject geeft een diverse inkijk in de problematiek van centrale-windingen-epilepsie, in het uitvoeren van klinische trials met medische apparatuur en in de toekomst van corticale hersenstimulatie bij epilepsie.
- 13 December 2023
- Published by Nederlandse Liga tegen Epilepsie in Epilepsie, periodiek voor professionals
- Vol. 22 (4)
Open AccessDe REC2STIM-studie: corticale netwerkstimulatie in een nieuw jasje
Binnenkort zal klinisch technoloog Dorien van Blooijs promoveren op corticale netwerkstimulatie als behandeling voor epilepsie. De totstandkoming van haar REC2STIM- studie heeft veel voeten in de aarde gehad, maar levert opmerkelijke inzichten en resultaten op. Daarnaast heeft zij met de spin-off van dit project een geweldige bijdrage geleverd aan de fysiologische kennis over de hersenen. Haar promotietraject geeft een diverse inkijk in de problematiek van centrale-windingen-epilepsie, in het uitvoeren van klinische trials met medische apparatuur en in de toekomst van corticale hersenstimulatie bij epilepsie.
- Open Access
- 8 June 2022
- Published by Nederlandse Liga tegen Epilepsie in Epilepsie, periodiek voor professionals
- Vol. 21 (2) , 7-8
Aanvalsdetectie en de creativiteit van technisch denken
Epilepsie, periodiek voor professionals is het kwartaalblad van de Nederlandse Liga tegen Epilepsie, de Nederlandse afdeling van de International League Against Epilepsy
- 8 June 2022
- Published by Nederlandse Liga tegen Epilepsie in Epilepsie, periodiek voor professionals
- Vol. 21 (2) , 7-8
Open AccessAanvalsdetectie en de creativiteit van technisch denken
Epilepsie, periodiek voor professionals is het kwartaalblad van de Nederlandse Liga tegen Epilepsie, de Nederlandse afdeling van de International League Against Epilepsy
- 1 October 2018
- Published by Elsevier in Clinical Neurophysiology
- Vol. 129 (10) , 2127-2131
Specific EEG markers in POLG1 Alpers’ syndrome
- 1 October 2018
- Published by Elsevier in Clinical Neurophysiology
- Vol. 129 (10) , 2127-2131
Specific EEG markers in POLG1 Alpers’ syndrome
- 1 February 2017
- Published by Elsevier in Epilepsy Research
- Vol. 130, 37-46
Central lobe epilepsy surgery – (functional) results and how to evaluate them
- 1 February 2017
- Published by Elsevier in Epilepsy Research
- Vol. 130, 37-46
Central lobe epilepsy surgery – (functional) results and how to evaluate them
- Open Access
- 1 February 2016
- Published by Elsevier in NeuroImage: Clinical
- Vol. 12, 928-939
High frequency oscillations and high frequency functional network characteristics in the intraoperative electrocorticogram in epilepsy
- 1 February 2016
- Published by Elsevier in NeuroImage: Clinical
- Vol. 12, 928-939
Open AccessHigh frequency oscillations and high frequency functional network characteristics in the intraoperative electrocorticogram in epilepsy
- 1 February 2016
- Published by Elsevier in Clinical Neurophysiology
- Vol. 127 (2) , 989-990
Generalized epilepsy: Don’t look too close
- 1 February 2016
- Published by Elsevier in Clinical Neurophysiology
- Vol. 127 (2) , 989-990
Generalized epilepsy: Don’t look too close
- Open Access
- 23 September 2015
- Published by Springer Nature in Trials
- Vol. 16 (1) , 1-10
High frequency oscillations in the intra-operative ECoG to guide epilepsy surgery (“The HFO Trial”): study protocol for a randomized controlled trial
Intra-operative electrocorticography, based on interictal spikes and spike patterns, is performed to optimize delineation of the epileptogenic tissue during epilepsy surgery. High frequency oscillations (HFOs, 80–500 Hz) have been identified as more precise biomarkers for epileptogenic tissue. The aim of the trial is to determine prospectively if ioECoG-tailored surgery using HFOs, instead of interictal spikes, is feasible and will lead to an equal or better seizure outcome. We present a single-blinded multi-center randomized controlled trial “The HFO Trial” including patients with refractory focal epilepsy of all ages who undergo surgery with intra-operative electrocorticography. Surgery is tailored by HFOs (arm 1) or interictal spikes (arm 2) in the intra-operative electrocorticography. Primary outcome is post-operative outcome after 1 year, dichotomized in seizure freedom (Engel 1A and 1B) versus seizure recurrence (Engel 1C-4). Secondary outcome measures are the volume of resected tissue, neurologic deficits, surgical duration and complications, cognition and quality of life. The trial has a non-inferiority design to test feasibility and at least equal performance in terms of surgical outcome. We aim to include 78 patients within 3 years including 1 year follow-up. Results are expected in 2018. This trial provides a transition from observational research towards clinical interventions using HFOs. We address methodological difficulties in designing this trial. We expect that the use of HFOs as a biomarker for tailoring will increase the success rate of epilepsy surgery while reducing resection volume. This may reduce neurological deficits and yield a better quality of life. Future technical developments, such as validated automatic online HFO identification, could, together with the attained clinical knowledge, lead to a new objective tailoring approach in epilepsy surgery. This trial is registered at the US National Institutes of Health (ClinicalTrials.gov) #NCT02207673 (31 July 2014) and the Central Committee on Research Involving Human Subjects, The Netherlands #NL44257.041.13 (18 March 2014).
- 23 September 2015
- Published by Springer Nature in Trials
- Vol. 16 (1) , 1-10
Open AccessHigh frequency oscillations in the intra-operative ECoG to guide epilepsy surgery (“The HFO Trial”): study protocol for a randomized controlled trial
Intra-operative electrocorticography, based on interictal spikes and spike patterns, is performed to optimize delineation of the epileptogenic tissue during epilepsy surgery. High frequency oscillations (HFOs, 80–500 Hz) have been identified as more precise biomarkers for epileptogenic tissue. The aim of the trial is to determine prospectively if ioECoG-tailored surgery using HFOs, instead of interictal spikes, is feasible and will lead to an equal or better seizure outcome. We present a single-blinded multi-center randomized controlled trial “The HFO Trial” including patients with refractory focal epilepsy of all ages who undergo surgery with intra-operative electrocorticography. Surgery is tailored by HFOs (arm 1) or interictal spikes (arm 2) in the intra-operative electrocorticography. Primary outcome is post-operative outcome after 1 year, dichotomized in seizure freedom (Engel 1A and 1B) versus seizure recurrence (Engel 1C-4). Secondary outcome measures are the volume of resected tissue, neurologic deficits, surgical duration and complications, cognition and quality of life. The trial has a non-inferiority design to test feasibility and at least equal performance in terms of surgical outcome. We aim to include 78 patients within 3 years including 1 year follow-up. Results are expected in 2018. This trial provides a transition from observational research towards clinical interventions using HFOs. We address methodological difficulties in designing this trial. We expect that the use of HFOs as a biomarker for tailoring will increase the success rate of epilepsy surgery while reducing resection volume. This may reduce neurological deficits and yield a better quality of life. Future technical developments, such as validated automatic online HFO identification, could, together with the attained clinical knowledge, lead to a new objective tailoring approach in epilepsy surgery. This trial is registered at the US National Institutes of Health (ClinicalTrials.gov) #NCT02207673 (31 July 2014) and the Central Committee on Research Involving Human Subjects, The Netherlands #NL44257.041.13 (18 March 2014).
- 1 June 2015
- Published by Elsevier in Epilepsy & Behavior
- Vol. 47, 39-44
Seizure precipitants in Dravet syndrome: What events and activities are specifically provocative compared with other epilepsies?
- 1 June 2015
- Published by Elsevier in Epilepsy & Behavior
- Vol. 47, 39-44
Seizure precipitants in Dravet syndrome: What events and activities are specifically provocative compared with other epilepsies?
- Open Access
- 19 July 2014
- Published by Springer Nature in BMC Neurology
- Vol. 14 (1) , 152
Prognosis and therapy of tumor-related versus non-tumor-related status epilepticus: a systematic review and meta-analysis
Status epilepticus (SE) is a medical emergency with high mortality rates. Of all SE’s, 7% are caused by a brain tumor. Clinical guidelines on the management of SE do not make a distinction between tumor-related SE and SE due to other causes. However, pathophysiological research points towards specific mechanisms of epilepsy in brain tumors. We investigated whether clinical features support a distinct profile of tumor-related SE by looking at measures of severity and response to treatment.
- 19 July 2014
- Published by Springer Nature in BMC Neurology
- Vol. 14 (1) , 152
Open AccessPrognosis and therapy of tumor-related versus non-tumor-related status epilepticus: a systematic review and meta-analysis
Status epilepticus (SE) is a medical emergency with high mortality rates. Of all SE’s, 7% are caused by a brain tumor. Clinical guidelines on the management of SE do not make a distinction between tumor-related SE and SE due to other causes. However, pathophysiological research points towards specific mechanisms of epilepsy in brain tumors. We investigated whether clinical features support a distinct profile of tumor-related SE by looking at measures of severity and response to treatment.